Adherium Limited (ASX.ADR) is an international Respiratory eHealth company focused on patient medication adherence, remote monitoring, and data management solutions for patients, payers, and providers.
Adherium’s Hailie® sensor technology and cloud-based data platform provides real-time feedback on patients' use of inhaled medication, enabling optimal management of difficult-to-treat and severe asthma and COPD, and reduce direct and indirect healthcare costs. Together with our strategic partners, we are developing new generation technology and working to deliver value to payers and providers, while maximizing the positive reimbursement environment with remote patient monitoring (RPM) payments now in place.
Adherium’s Hailie® digital solution comprises patented sensors and proprietary algorithms that track medication delivery, capturing data for clinicians and generating auditable reimbursement reports for payers and providers.
• Most clinical evidence of any digital respiratory monitor (>85 studies involving 13,000 patients)
• Clinically proven to improve adherence and outcomes
• >170,000 devices sold in 30 countries
• Widest US inhaler market coverage
• Funded technology upgrade will access US reimbursement
Adherium’s Hailie® sensor technology and cloud-based data platform provides real-time feedback on patients' use of inhaled medication, enabling optimal management of difficult-to-treat and severe asthma and COPD, and reduce direct and indirect healthcare costs. Together with our strategic partners, we are developing new generation technology and working to deliver value to payers and providers, while maximizing the positive reimbursement environment with remote patient monitoring (RPM) payments now in place.
Adherium’s Hailie® digital solution comprises patented sensors and proprietary algorithms that track medication delivery, capturing data for clinicians and generating auditable reimbursement reports for payers and providers.
• Most clinical evidence of any digital respiratory monitor (>85 studies involving 13,000 patients)
• Clinically proven to improve adherence and outcomes
• >170,000 devices sold in 30 countries
• Widest US inhaler market coverage
• Funded technology upgrade will access US reimbursement
Location: New Zealand, Auckland
Employees: 11-50
Total raised: $3M
Founded date: 2001
Investors 4
| Date | Name | Website |
| - | New Zealan... | nzgcp.co.n... |
| - | Bioscience... | bioscience... |
| - | Cure Kids ... | curekidsve... |
| - | Icehouse V... | icehouseve... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.08.2015 | - | $3M | - |
Mentions in press and media 12
| Date | Title | Description |
| 15.09.2025 | New Data, iCARE Study: Hailie® Smartinhaler® Powers Unprecedented Medication Adherence in Patients with COPD and Asthma | Highlights: Up to 235% increase in real-world adherence compared to published norms (20–40%), across ~850 chronic obstructive pulmonary disease (COPD) and asthma patients. >60% patients achieved an average two-week baseline adherence wit... |
| 13.12.2018 | How traditional pharmacies can survive the Amazon threat | Are traditional pharmacies doomed to the same fate as Borders, Blockbuster, and Sears? The threat is real. Companies like Capsule and PillPack are redesigning the pharmacy for the digital age. In addition to making it effortless to get pres... |
| 02.04.2018 | Adherium gets FDA clearance for OTC sales of sensor to support asthma medication management | The sensor attaches to the user’s inhaler and tracks their daily usage. The company’s sensor records the date and time the device was used and automatically transmits this information to an app on the patient’s phone or tablet. The SmartTou... |
| 25.01.2018 | New Zealand remote monitoring tech for COPD, asthma opens U.S. offices | In an interview, CEO Arik Anderson told MobiHealthNews that SmartTouch is keen to work with insurance companies and with pharmacies to get its adherence solutions into the hands of patients where it will dramatically improve their lives. “A... |
| 01.09.2017 | In collaboration with AstraZeneca, Adherium CEO shares evolution of patient engagement approach for asthma, COPD | “Initially we were looking at stand alone inhaler devices with sensors able to detect when the device was activated,” Anderson said. “We have evolved beyond whether the patient is using the device to whether the patient is using the device ... |
| 20.07.2016 | Smart inhaler company Adherium raises $5.9M from Fidelity | Adherium, a Melbourne, Australia-based connected inhaler company, has raised $5.9 million ($8 million Australian) through a private placement of shares with Fidelity. Adherium is publicly traded in Australia. Under the deal, Fidelity will p... |
| 03.12.2015 | 5 digital health tools that could improve COPD management | LifeMap Solutions has launched its COPD Navigator app for iOS devices. It was developed through a partnership with Icahn School of Medicine at Mount Sinai and pulmonologists from the Mount Sinai – National Jewish Health Respiratory Institut... |
| 19.08.2015 | AstraZeneca invests $3M in NZ smart inhaler maker Adherium | Adherium Limited, a New Zealand company working on a smart inhaler, has raised $25.6 million ($35 million AU) in an initial public offering on the Australian Securities Exchange, including a $3 million investment from its partner pharma com... |
| - | 5 digital health tools that could improve COPD management | This post has been updated from an earlier version to reflect comments from LifeMap Solutions CEO Corey Bridges. COPD affects 24 million people and is the third leading cause of death in the U.S. Punitive fines to reduce readmission rates f... |
| - | New Zealand remote monitoring tech for COPD, asthma opens U.S. offices | Four months after Adherium secured FDA clearance for an inhaler sensor called SmartTouch for use with AstraZeneca’s Symbicort aerosol inhaler for patients with COPD and asthma, the company has opened up offices in San Mateo to pave the way ... |
Show more